First-passage time analysis of diffusion-controlled reactions in single-molecule detection

Lyu, Yingkai; An, Li-Xiang; Zeng, Huaiyang; Feng, Zhenghe; Guo, Jiajia; Zhang, Pengcheng; Ye, Hui; Li, Hao

doi:10.1016/j.talanta.2023.124569

Cited by 1 publication

(1 citation statement)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These considerations lay the groundwork for understanding why single molecule detections are influenced by two interconnected issues: diffusion barrier and low signal-to-noise ratio. The diffusion barrier issue [58,59] refers to the challenge for an individual molecule to reach the transducing interface by Brownian random diffusion in a volume (0.1 mL) that is 10 17 times larger than the molecule itself. The time needed to hit a capturing interface generating the signal to be transduced, can be unfeasibly high, particularly if the area of the detecting interface is nanometric in size.…”

Section: The Challenge Of Reliably Detecting a Single Molecule In 01 MLmentioning

confidence: 99%

Point‐Of‐Care Ultra‐Portable Single‐Molecule Bioassays for One‐Health

Macchia,

Torricelli,

Caputo

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Screening asymptomatic organisms (humans, animals, plants) with a high‐diagnostic accuracy using point‐of‐care‐testing (POCT) technologies, though still visionary holds great potential. Convenient surveillance requires easy‐to‐use, cost‐effective, ultra‐portable but highly reliable, in‐vitro‐diagnostic devices that are ready for use wherever they are needed. Currently, there are not yet such devices available on the market, but there are a couple more promising technologies developed at readiness‐level 5: the Clustered‐Regularly‐Interspaced‐Short‐Palindromic‐Repeats (CRISPR) lateral‐flow‐strip tests and the Single‐Molecule‐with‐a‐large‐Transistor (SiMoT) bioelectronic palmar devices. They both hold key features delineated by the World‐Health‐Organization for POCT systems and an occurrence of false‐positive and false‐negative errors <1–5% resulting in diagnostic‐selectivity and sensitivity >95–99%, while limit‐of‐detections are of few markers. CRISPR‐strip is a molecular assay that, can detect down to few copies of DNA/RNA markers in blood while SiMoT immunometric and molecular test can detect down to a single oligonucleotide, protein marker, or pathogens in 0.1mL of blood, saliva, and olive‐sap. These technologies can prospectively enable the systematic and reliable surveillance of asymptomatic ones prior to worsening/proliferation of illnesses allowing for timely diagnosis and swift prognosis. This could establish a proactive healthcare ecosystem that results in effective treatments for all living organisms generating diffuse and well‐being at efficient costs.

show abstract

Section: The Challenge Of Reliably Detecting a Single Molecule In 01 MLmentioning

confidence: 99%